Raymond James Reaffirms Outperform Rating for Knight Therapeutics (GUD)  Fairfield Current

Raymond James reaffirmed their outperform rating on shares of Knight Therapeutics (TSE:GUD) in a report released on Wednesday, January 16th. Raymond …